betty and guy beatty center for integrated - Inova Health System

I NOVA HEART AND VASCULAR INSTITUTE ( IHVI)
ADVANCED LUNG DISEASE
The Inova Advanced Lung Disease and Transplant Program is dedicated
to the care of patients with many forms of advanced lung disease, including
conditions such as chronic obstructive pulmonary disease, idiopathic
pulmonary fibrosis (IPF), pulmonary hypertension (PH), cystic fibrosis,
and sarcoidosis.
The research program has numerous facets including pharmaceutical
drug trials of medications for IPF, PH, and lung transplantation, and active
clinical and research collaboration with the NIH through the intramurally
funded NIH-Inova Advanced Lung Disease Program. Genomics research
into IPF is conducted through a collaboration with George Mason
University. In addition, original Inova investigator initiated projects account
for most of the publications emanating from the Program. The Program
has also collaborated with esteemed research institutions such as
the Cleveland Clinics, Mayo Clinic, UCLA, Johns Hopkins, The University
of Florida, the University of Pittsburgh, and Vanderbilt University. In
close collaborative environment, and most importantly the patients themselves,
who continue to empower and enable the research by their willingness
to participate in the clinical trials.
BOOKS, BOOK CHAPTERS, AND JOURNAL ARTICLES
1. Shlobin OA, Nathan SD. Interstitial lung disease and pulmonary hy
pertension. (edited by Robert Baughman, MD and Ronald du Bois,
MD)
2. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin O, Osei K,
Zaiman AL, Hassoun PM, Moller DR, Barnett SD, Girgis RE. The
Treatment of sarcoidosis associated pulmonary hypertension: a two
center experience. Chest 2009;;135:1455-1461
3. El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg B, Pacheco-
Rodriguez G, Rosas I, MacDonald SD, Wu H, Nathan SD, Cutitta F,
McCoy JP, Gochuico BR, Moss J. Abnormal Lymphangiogenesis in
Idiopathic Pulmonary Fibrosis: Insights into Cellular and Molecular
Mechanisms.PNAS2009http://www/pnas.org/content/
early/2009/02/20/0813368106.abstract
4. King CS, Khandhar S, Burton N, Shlobin OA, Ahmad S, Barnett SD,
Nathan SD. Native Lung Complications In Single Lung Transplant
Recipients And the Role of Pneumonectomy. J Heart Lung Trans
plant 2009;;28:851-6
5. Nathan SD, Shlobin OA, Reese E, Ahmad S, Fregoso M, Athale C,
Barnett SD. The Prognostic Value of the Six-minute Walk Test in Pa
tients with Bronchiolitis Obliterans Syndrome. Respiratory Medicine
2009;;103:1816-21.
6. Sunde JS, Chetty-John S, Shlobin OA, Boice C, Rose GS. Epstein-
Barr Virus Associated Uterine Leiomyosarcoma in an Adult Lung
Transplant Patient. Accepted to Obstetrics and Gynecology.
ABSTRACTS AND PRESENTATIONS TO NATIONAL/
INTERNATIONAL MEETINGS
1. Shlobin OA, Edwards E, Nathan SD. Waiting Times and Mortality for
IPF Patients Listed for Bilateral or Single Lung Transplantation. J
Heart Lung Transplant 2009;;28:S168.
2. S Ahmad, OA Shlobin, SD Barnett, EA Lefrak, ME Schmidt, N Bur
ton, SD Nathan. Cytomegaloviral Shedding in Bronchoalveolar Lav
������ ���� ���������� ��������� ��������� ��� ���������
age (BAL)
���������
in Lung Transplant
���������
Recipients:
���
Comparison of Oral Val
pers published or submitted to the peer-reviewed literature, and 22 pres-
ganciclovir to IV and Oral Ganciclovir Based Prophylactic Regimens.
entations at or submitted to international meetings. The research pro-
Am J Respir Crit Care Med 2009;;179:A4609
gram owes its success to the dedication of our research coordinators, a
3. S Kilaru, OA Shlobin, S Ahmad, SD Barnett, SD Nathan. Combined
P AGE 34